
- Oncology NEWS International Vol 11 No 10
- Volume 11
- Issue 10
Compact, Dedicated Breast PET Scanner Being Developed
WASHINGTON-The imaging methods presently used to detect, diagnose, and stage breast tumors have significant flaws, as shown by the roughly 75% of breast biopsies that return normal results. These "completely unnecessary" procedures impose "huge costs" and "unnecessary trauma," said Craig S. Levin, PhD, assistant professor of radiology, University of California, San Diego, and the Department of Nuclear Medicine, San Diego VA Medical Center.
WASHINGTONThe imaging methods presently used to detect, diagnose, and stage breast tumors have significant flaws, as shown by the roughly 75% of breast biopsies that return normal results. These "completely unnecessary" procedures impose "huge costs" and "unnecessary trauma," said Craig S. Levin, PhD, assistant professor of radiology, University of California, San Diego, and the Department of Nuclear Medicine, San Diego VA Medical Center.
Although positron emission tomography (PET) imaging offers a potential alternative, existing PET systems have significant drawbacks as breast imaging devices, he said. Designed for whole-body coverage, they are large and entail "difficult geometry" in capturing the breast. Studies currently are expensive and result in "nonoptimal" breast images.
One potential solution could be a compact dedicated PET device using an improved sensor system in a "very compact" camera, he said at the Susan G. Komen Breast Cancer Foundation 5th Annual Conference on Innovations in Quality Care. The camera could be placed "right up against the breast," he said, and could also "move to other areas," such as the axilla. Dr. Levin’s team have built a laboratory at the San Diego VA Medical Center dedicated to this project. They currently are developing a "detector" for sensing and localizing positron energy.
Early results show that the new detector will produce spatial resolution five times better than existing PET scanners. Such high resolution suggests that the detector might eventually find currently undetected very small tumors.
Dr. Levin emphasized that "a lot of this is hypothetical" at present. He also stressed that the detector is not "meant to replace present technology," but rather to provide "an additional tool when present methods are inconclusive."
Articles in this issue
about 23 years ago
FDG-PET Predicts Prognosis in Primary Osteosarcomaabout 23 years ago
Vaccine Turns Immune System Against Cancer Cellsabout 23 years ago
Three Themes to Guide von Eschenbach at NCIabout 23 years ago
Arimidex Approved for Early-Stage Breast Cancer in Postmenopausal Ptsabout 23 years ago
Long-Term Exposure to Diesel Exhaust Poses Lung Cancer Riskabout 23 years ago
Most Americans Unaware of Excessive Weight as a Risk for Some Cancersabout 23 years ago
Three Themes to Guide von Eschenbach as NCI Directorabout 23 years ago
Gleevec Gets FDA Priority Review for First-Line Use in Early CMLabout 23 years ago
New Anti-HIV Agent Prevents Virus From Entering Cellabout 23 years ago
Docetaxel/Gemcitabine Effective in Advanced NSCLCNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.